In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Eli Lilly, Ono develop and market respiratory pharmaceutical

Executive Summary

Eli Lilly signed a letter of intent for an exclusive worldwide license--except in Japan, South Korea, and Taiwan--to Ono Pharmaceutical's (prostaglandins and enzyme inhibitors) Phase II sivelestat for acute lung injury and acute respiratory distress syndrome requiring mechanical ventilation.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register